What antiemetic agents and dosing regimens are recommended for each age group (neonates, infants/children, adolescents, adults, and elderly patients)?

Commonly Used Antiemetics According to Age

The choice of antiemetic varies significantly by age group, with ondansetron being the safest and most effective first-line agent across pediatric populations, while adults have broader options including 5-HT3 antagonists, NK1 receptor antagonists, dexamethasone, and olanzapine depending on clinical context.

Neonates and Infants

For the youngest patients, evidence is extremely limited. Ondansetron remains the preferred agent when antiemetics are necessary, though use should be judicious given the self-limiting nature of most causes of vomiting in this age group 1. Dosing must be weight-based and carefully calculated.

Key Considerations:

• Avoid promethazine due to sedation risks and potential respiratory depression
• Metoclopramide carries high risk of extrapyramidal reactions (EPRs) in young children
• Most gastroenteritis cases are self-limiting and oral rehydration therapy should be prioritized

Children (1-12 years)

Ondansetron is the clear first-line antiemetic for children, demonstrating superior efficacy and safety compared to all other agents 2, 1.

Dosing Recommendations:

• Ondansetron: 0.15 mg/kg IV or 8 mg oral (for gastroenteritis-related vomiting)
• Single dose reduces vomiting, facilitates oral rehydration, and decreases hospitalization rates 1

For Chemotherapy-Induced Nausea/Vomiting (CINV):

The pediatric oncology population requires more aggressive regimens 3:

• 5-HT3 antagonists (ondansetron, granisetron, palonosetron)
• Dexamethasone: 6-32 mg/m²/day (significant dosing variability exists; reduce by 30% when combined with aprepitant)
• Aprepitant: 80 mg capsules for children 15-40 kg for 1-3 days 4
  • Limited by lack of oral suspension formulations in many countries
  • Well-tolerated when added to standard regimens
• Olanzapine: 0.1-0.14 mg/kg/day (newer agent with good efficacy but monitor for sedation and hyperglycemia) 3

Agents to Avoid or Use Cautiously:

• Metoclopramide: High EPR risk (15% at ≥2 mg/kg doses), especially with consecutive-day dosing 5
• Dimenhydrinate: Only antiemetic worse than placebo for side effects 1
• Promethazine: Excessive sedation, risk of vascular damage with IV administration 6

Adolescents (13-17 years)

Adolescents can generally tolerate adult-equivalent regimens but remain at higher risk for EPRs than older adults.

Standard Approach:

• Ondansetron: 8 mg oral/IV remains first-line for acute vomiting 6
• For CINV: Use adult protocols with 5-HT3 antagonists + dexamethasone ± NK1 antagonists 7
• Prochlorperazine or metoclopramide: Can be used but monitor closely for akathisia (can develop up to 48 hours post-administration; treat with diphenhydramine if occurs) 6

Adults

Adults have the most extensive antiemetic options, with selection based on clinical context (chemotherapy, radiation, postoperative, general nausea).

First-Line Options by Setting:

Emergency Department/Acute Vomiting 6:

• Ondansetron: 8 mg IV/oral (safest, no sedation or akathisia)
• Prochlorperazine: 10 mg PO/IV every 6 hours (monitor for akathisia; slow infusion rate reduces incidence)
• Metoclopramide: 10-20 mg PO/IV every 4-6 hours (similar akathisia risk)
• Promethazine: 12.5-25 mg (use when sedation is desirable)

Highly Emetogenic Chemotherapy (HEC) 7:

• Day 1 regimen (Category 1 evidence):
  • 5-HT3 antagonist (ondansetron 8 mg, granisetron 1-2 mg, or palonosetron) +
  • Dexamethasone 12 mg +
  • NK1 antagonist (aprepitant, fosaprepitant, or rolapitant)
• Alternative: Olanzapine 5-10 mg + palonosetron + dexamethasone
• Days 2-4: Modified dosing of above agents

Moderately Emetogenic Chemotherapy (MEC) 7:

• Dexamethasone + 5-HT3 antagonist ± NK1 antagonist
• Consider adding NK1 antagonist for patients with additional risk factors

Breakthrough CINV 7: Add agent from different drug class:

• Olanzapine: 5-10 mg PO daily (Category 1)
• Metoclopramide: 10-20 mg PO/IV every 4-6 hours
• Prochlorperazine: 10 mg PO/IV every 6 hours or 25 mg PR every 12 hours
• Lorazepam: 0.5-2 mg every 6 hours (for anxiety component)
• Haloperidol: 0.5-2 mg every 4-6 hours

Radiation Therapy 8: Dosing varies by anatomic site and emetogenic risk (high/moderate/low/minimal)

• High risk (total body irradiation): Ondansetron 8 mg + dexamethasone 4 mg
• Moderate risk (upper abdomen): Same as high risk
• Low risk (brain, head/neck, thorax, pelvis): 5-HT3 antagonist ± dexamethasone ± dopamine antagonist

Agents with Special Considerations:

• Droperidol: More effective than prochlorperazine or metoclopramide but FDA black box warning for QT prolongation limits use to refractory cases 6
• Dexamethasone: Avoid or use cautiously with immune checkpoint inhibitors (may attenuate benefit) 8

Elderly Patients

Elderly patients generally tolerate antiemetics better than younger adults, with lower EPR risk, but require dose adjustments for renal/hepatic impairment.

Recommended Approach:

• Ondansetron: Remains first-line (8 mg oral/IV)
• Lower EPR risk: Can use metoclopramide or prochlorperazine more safely than in younger populations 5
• Caution with sedating agents: Promethazine increases fall risk
• Monitor QTc: Especially with ondansetron, droperidol, or multiple QT-prolonging medications 3

Critical Drug Interactions:

When prescribing antiemetics in elderly patients receiving chemotherapy, monitor for:

• QTc prolongation (5-HT3 antagonists + azole antifungals, arsenic trioxide)
• Enhanced sedation with benzodiazepines
• Dexamethasone dose reduction (30% decrease) when combined with aprepitant

Common Pitfalls to Avoid

1. Using metoclopramide or prochlorperazine without warning patients about akathisia - this distressing side effect can occur up to 48 hours after administration and is often mistaken for anxiety 6

2. Prescribing promethazine IV peripherally - risk of vascular damage; use central line only 7

3. Failing to adjust dexamethasone dose when combining with NK1 antagonists (30% reduction needed in children, 50% in adults) 3

4. Using dimenhydrinate in children - worse side effect profile than placebo 1

5. Overlooking palonosetron's faster metabolism in children - requires higher dosing than adults for equivalent efficacy 3

6. Prescribing droperidol without ECG monitoring - FDA black box warning for QT prolongation 6